Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
|Articles|June 9, 2011
AMCP 2011: Interview with Dr. Jeffrey Dunn of SelectHealth, Salt Lake City, Utah
Dr. Jeffrey Dunn describes the trends and practices for managing oncology-related treatments.
Advertisement
Dr. Jeffrey Dunn, Formulary and Contract Manager at SelectHealth in Salt Lake City, Utah, discusses oncology medications in the pipeline, cost and the importance of collaboration.
Advertisement
Related to this article
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5